Stay updated on Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    Publications description updated to indicate that items are automatically filled from PubMed and may not be about the study, and the Revision label changed from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-24T17:06:12.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Removed the funding/operating status notice from the page. The study details and related information remain unchanged.
    Difference
    0.3%
    Check dated 2025-11-17T15:05:34.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    Both screenshots show the same page sections and information for Study NCT03331341; no additions or deletions are evident.
    Difference
    0.4%
    Check dated 2025-11-03T01:34:32.000Z thumbnail image
  6. Check
    71 days ago
    Change Detected
    Summary
    - Added a government funding notice and operating status guidance, plus a pointer to cc.nih.gov; - Bumped version from v3.1.0 to v3.2.0.
    Difference
    3%
    Check dated 2025-10-05T12:52:05.000Z thumbnail image
  7. Check
    78 days ago
    Change Detected
    Summary
    Version updated from v3.0.2 to v3.1.0; no substantive content changes detected.
    Difference
    0.1%
    Check dated 2025-09-28T09:35:26.000Z thumbnail image
  8. Check
    93 days ago
    Change Detected
    Summary
    Updated the page revision from v3.0.1 to v3.0.2 and removed the Back to Top element; no substantive changes to core content, pricing, or scheduling.
    Difference
    0.2%
    Check dated 2025-09-14T00:15:22.000Z thumbnail image

Stay in the know with updates to Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page.